At 36 weeks in the TOGETHER-PsO study, concomitant Taltz and Zepbound met primary endpoint of superiority vs. Taltz monotherapy in achieving complete skin clearance (PASI 100) and ≥10% weight loss In ...
By Sriparna Roy May 28 (Reuters) - CVS Health will restore Eli Lilly's weight-loss injection Zepbound to its list of covered ...
CVS Health said it will restore coverage of Eli Lilly's blockbuster weight loss injection Zepbound and start covering its new obesity pill on its standard drug plans. The move supports Lilly's efforts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results